Stocks to watch: Yangzijiang Financial, Marco Polo Marine, China Medical Systems, Clearbridge Health

The following companies saw new developments that may affect trading of their securities on Tuesday (Aug 19):

Yangzijiang Financial: The investment holding company said on Monday that it will be the anchor investor in a S$100 million fund by ICH Asset Management, led by Vincent Toe, the Singapore-listed company’s former chief executive. The fund will focus exclusively on Singapore’s small and medium-sized enterprises and is expected to start investing from September this year. The group did not specify the exact sum it would invest in the fund, though it did state the initial pipeline of opportunities include companies from the sectors of healthcare, technology, sustainability, and consumer-services. Shares of Yangzijiang Financial ended Monday flat at S$1.06 before the news.

Marco Polo Marine: The integrated marine logistics group on Monday posted a 4 per cent decline in gross profit to S$14 million for its third quarter ended Jun 30, 2025, from S$14.6 million in the year-ago period. Its revenue fell 9 per cent on the year to S$31.7 million, from S$34.9 million previously. Shares of Marco Polo Marine ended Monday unchanged at S$0.065, before the announcement.

(CMS): The pharmaceutical company posted a rise in first half profit and declared an interim dividend on Monday, its first set of results after its secondary listing on the Singapore Exchange. Net profit rose 3.4 per cent to 941.2 million yuan (S$168.3 million) compared to the year ago period, as the negative impact of China’s national volume-based procurement policy declined and sales of the group’s products grew. Shares of CMS closed Monday 0.905 per cent or S$0.02 up at S$2.23.

Clearbridge Health: The healthcare company said on Monday that it has raisedS$1.98 million in a fully subscribed placement of 990 million shares, at S$0.002 each. This has been backed by Singapore fund manager Azure Capital, family office Asdew Acquisitions and veteran investor Ramesh Chandiramani, on plans to enter a new business through the acquisition of biopharma company Elpis Biopharmaceuticals for US$330 million. The placement has allowed Clearbridge to become debt-free, and the proceeds will be used to fund the planned acquisition and for general working capital. The counter ended Monday flat at S$0.004 before the news.

Share with us your feedback on BT's products and services